Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma |
| |
| Authors: | Meera Mohan Rajshekhar Chakraborty Susan Bal Anoma Nellore Muhamed Baljevic Anita D'Souza Peter G Pappas Jesus G Berdeja Natalie Callander Luciano J Costa |
| |
| Institution: | 1. Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA;2. Multiple Myeloma and Amyloidosis Program, Herbert Irving Comprehensive Cancer Center, Columbia University, New York City, New York, USA;3. Division of Hematology and Medical Oncology, University of Alabama at Birmingham, Birmingham, Alabama, USA;4. Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama, USA;5. Division of Hematology/Oncology, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, USA;6. Sarah Cannon Research Institute, Nashville, Tennessee, USA;7. Department of Medicine, Division of Hematology and Oncologye, University of Wisconsin, Madison, Wisconsin, USA |
| |
| Abstract: | Chimeric antigen receptor T (CAR T) cell and bispecific antibody therapies have shown unprecedented efficacy in heavily pretreated patients with multiple myeloma (MM). However, their use is associated with a significant risk of severe infections, which can be attributed to various factors such as hypogammaglobulinemia, neutropenia, lymphopenia, T-cell exhaustion, cytokine-release syndrome and immune-effector cell-associated neurotoxicity syndrome. As these therapies have been recently approved by regulatory agencies, it is crucial to establish practical guidelines for infection monitoring and prevention until robust data from prospective clinical trials become available. To address this issue, a panel of experienced investigators from the Academic Consortium to Overcome Multiple Myeloma through Innovative Trials (COMMIT) developed consensus recommendations for mitigating infections associated with CAR T-cell and bispecific antibody therapies in MM patients. |
| |
| Keywords: | bispecific T-cell chimeric antigen receptor T-cell immunotherapy infection multiple myeloma |
|
|
